Share This

Related Topics News -

     
 Title only   |   Print 
     
《大行》建銀國際微升信達生物目標價至54.7元 有信心銷售增長更光明

2024-05-03T  
《大行》里昂升信達生物目標價至58.1元 首季業績強勁

2024-05-03T  
信達生物首季總產品收入按年增逾60%至逾17億人幣

2024-04-30T  
信達生物治療子宮內膜癌新藥上市申請獲內地受理並授予優先審評

2024-04-02T  
《大行報告》匯豐研究升信達生物目標價至55元 收支平衡指日可待

2024-03-26T  

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2024 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.